Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
24 Oktober 2023 - 1:01PM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced that it plans to release
financial results for the third quarter ended September 30, 2023 on
November 7, 2023. The Company will host a conference call at 8:30
a.m. Eastern Time on November 7, 2023.
Participants may access the conference call via webcast on the
Investors and Media page of Marinus’ website at
ir.marinuspharma.com/events-and-presentations. An archived version
of the call will be available approximately two hours after the
completion of the event on the website.
About Marinus Pharmaceuticals Marinus is a
commercial-stage pharmaceutical company dedicated to the
development of innovative therapeutics for seizure disorders. The
Company first introduced FDA-approved prescription medication
ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and
continues to invest in the potential of ganaxolone in IV and oral
formulations to maximize therapeutic reach for adult and pediatric
patients in acute and chronic care settings. For more information
about Marinus visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231024565228/en/
Investors Jim DeNike Senior
Director, Investor Relations Marinus Pharmaceuticals,
Inc. jdenike@marinuspharma.com
Media Molly Cameron Director,
Corporate Communications & Investor Relations Marinus
Pharmaceuticals, Inc. mcameron@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024